The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| AADI BIOSCIENCES INC | Common | 00032Q104 | 20,629,670 | 2,849,402 | SH | SOLE | 2,849,402 | 0 | 0 | |||
| ALNYLAM PHARMACEUTICALS INC | Common | 02043Q107 | 221,353,600 | 1,105,000 | SH | SOLE | 1,105,000 | 0 | 0 | |||
| AMICUS THERAPEUTICS INC | Common | 03152W109 | 302,757,000 | 27,300,000 | SH | SOLE | 27,300,000 | 0 | 0 | |||
| AMYLYX PHARMACEUTICALS INC | Common | 03237H101 | 13,880,754 | 473,100 | SH | SOLE | 473,100 | 0 | 0 | |||
| APELLIS PHARMACEUTICALS INC | Common | 03753U106 | 732,888,882 | 11,111,111 | SH | SOLE | 11,111,111 | 0 | 0 | |||
| ARGENX SE | Sponsored ADR | 04016X101 | 479,696,750 | 1,287,500 | SH | SOLE | 1,287,500 | 0 | 0 | |||
| ASCENDIS PHARMA | Sponsored ADR | 04351P101 | 356,506,500 | 3,325,000 | SH | SOLE | 3,325,000 | 0 | 0 | |||
| AVIDITY BIOSCIENCES INC | Common | 05370A108 | 38,528,500 | 2,510,000 | SH | SOLE | 2,510,000 | 0 | 0 | |||
| BIOCRYST PHARMACEUTICALS INC | Common | 09058V103 | 86,902,800 | 10,420,000 | SH | SOLE | 10,420,000 | 0 | 0 | |||
| BIOMARIN PHARMACEUTICAL INC | Common | 09061G101 | 383,611,800 | 3,945,000 | SH | SOLE | 3,945,000 | 0 | 0 | |||
| CYMABAY THERAPEUTICS INC | Common | 23257D103 | 89,816,000 | 10,300,000 | SH | SOLE | 10,300,000 | 0 | 0 | |||
| DESIGN THERAPEUTICS INC | Common | 25056L103 | 20,195,000 | 3,500,000 | SH | SOLE | 3,500,000 | 0 | 0 | |||
| DICE THERAPEUTICS INC | Common | 23345J104 | 113,167,500 | 3,950,000 | SH | SOLE | 3,950,000 | 0 | 0 | |||
| FENNEC PHARMACEUTICALS INC | Common | 31447P100 | 9,984,000 | 1,200,000 | SH | SOLE | 1,200,000 | 0 | 0 | |||
| HORIZON THERAPEUTICS PLC | Common | G46188101 | 763,980,000 | 7,000,000 | SH | SOLE | 7,000,000 | 0 | 0 | |||
| IO BIOTECH INC | Common | 449778109 | 3,844,501 | 2,055,883 | SH | SOLE | 2,055,883 | 0 | 0 | |||
| IOVANCE BIOTHERAPEUTICS INC | Common | 462260100 | 42,892,200 | 7,020,000 | SH | SOLE | 7,020,000 | 0 | 0 | |||
| IVERIC BIO INC | Common | 46583P102 | 1,837,500 | 875,000 | SH | Call | SOLE | 875,000 | 0 | 0 | ||
| IVERIC BIO INC | Common | 46583P102 | 165,444,000 | 6,800,000 | SH | SOLE | 6,800,000 | 0 | 0 | |||
| KRYSTAL BIOTECH INC | Common | 501147102 | 140,105,000 | 1,750,000 | SH | SOLE | 1,750,000 | 0 | 0 | |||
| KURA ONCOLOGY INC | Common | 50127T109 | 37,974,150 | 3,105,000 | SH | SOLE | 3,105,000 | 0 | 0 | |||
| KYMERA THERAPEUTICS INC | Common | 501575104 | 114,223,650 | 3,855,000 | SH | SOLE | 3,855,000 | 0 | 0 | |||
| MADRIGAL PHARMACEUTICALS INC | Common | 558868105 | 403,766,505 | 1,666,666 | SH | SOLE | 1,666,666 | 0 | 0 | |||
| MANNKIND CORP | Common | 56400P706 | 37,310,000 | 9,100,000 | SH | SOLE | 9,100,000 | 0 | 0 | |||
| MARINUS PHARMACEUTICALS INC | Common | 56854Q200 | 21,735,000 | 3,150,000 | SH | SOLE | 3,150,000 | 0 | 0 | |||
| MERSANA THERAPEUTICS INC | Common | 59045L106 | 31,030,500 | 7,550,000 | SH | SOLE | 7,550,000 | 0 | 0 | |||
| MIRATI THERAPEUTICS INC | Common | 60468T105 | 206,555,535 | 5,555,555 | SH | SOLE | 5,555,555 | 0 | 0 | |||
| MONTE ROSA THERAPEUTICS INC | Common | 61225M102 | 33,691,750 | 4,325,000 | SH | SOLE | 4,325,000 | 0 | 0 | |||
| NUVALENT INC | Common | 670703107 | 49,281,088 | 1,888,888 | SH | SOLE | 1,888,888 | 0 | 0 | |||
| PMV PHARMACEUTICALS INC | Common | 69353Y103 | 14,596,200 | 3,060,000 | SH | SOLE | 3,060,000 | 0 | 0 | |||
| SAREPTA THERAPEUTICS INC | Common | 803607100 | 503,079,500 | 3,650,000 | SH | SOLE | 3,650,000 | 0 | 0 | |||
| SAREPTA THERAPEUTICS INC | Common | 803607100 | 3,675,000 | 250,000 | SH | Call | SOLE | 250,000 | 0 | 0 | ||
| SEAGEN INC | Common | 81181C104 | 364,831,908 | 1,801,906 | SH | SOLE | 1,801,906 | 0 | 0 | |||
| SERES THERAPEUTICS INC | Common | 81750R102 | 7,342,650 | 1,295,000 | SH | SOLE | 1,295,000 | 0 | 0 | |||
| SYNDAX PHARMACEUTICALS INC | Common | 87164F105 | 55,968,000 | 2,650,000 | SH | SOLE | 2,650,000 | 0 | 0 | |||
| TANGO THERAPEUTICS INC | Common | 87583X109 | 6,478,000 | 1,640,000 | SH | SOLE | 1,640,000 | 0 | 0 | |||
| ULTRAGENYX PHARMACEUTICAL INC | Common | 90400D108 | 30,075,000 | 750,000 | SH | SOLE | 750,000 | 0 | 0 | |||
| UNITED THERAPEUTICS CORP | Common | 91307C102 | 642,765,200 | 2,870,000 | SH | SOLE | 2,870,000 | 0 | 0 | |||
| VERRICA PHARMACEUTICALS INC | Common | 92511W108 | 17,225,000 | 2,650,000 | SH | SOLE | 2,650,000 | 0 | 0 | |||
| SPDR SERIES TRUST - S&P BIOTECH | ETF | 78464A870 | 180,000 | 1,500,000 | SH | Call | SOLE | 1,500,000 | 0 | 0 | ||
| XENON PHARMACEUTICALS INC | Common | 98420N105 | 175,371,000 | 4,900,000 | SH | SOLE | 4,900,000 | 0 | 0 | |||